Outlook Therapeutics (OTLK) Assets (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Assets of $21.9 million for Q1 2026, up 14.77% year-over-year from $19.1 million in Q1 2025, and up 20.03% quarter-over-quarter from $18.2 million in Q4 2025.
Outlook Therapeutics (OTLK) Assets (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Assets for 12 consecutive years, with $21.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 14.77% year-over-year to $21.9 million; the TTM figure through Mar 2026 stood at $21.9 million (up 14.77% YoY), while the FY2025 annual figure was $18.6 million, down 35.52% from the prior year.
- Assets improved to $21.9 million in Q1 2026 per OTLK's latest filing, from $18.2 million in the prior quarter.
- Across five years, Assets topped out at $67.7 million in Q1 2022 and bottomed at $17.0 million in Q4 2024.
- Historically, Assets has averaged $35.4 million across 5 years, with a median of $28.8 million in 2024.
- Annual changes were most pronounced in 2022 — Assets jumped 50.04% — and 2025, when it slumped 67.68%.
- Outlook Therapeutics' Assets stood at $62.7 million in 2022, then plunged by 65.41% to $21.7 million in 2023, then retreated by 21.58% to $17.0 million in 2024, then advanced by 7.25% to $18.2 million in 2025, then gained by 20.03% to $21.9 million in 2026.
- Business Quant data shows OTLK's Assets at $21.9 million in Q1 2026, $18.2 million in Q4 2025, and $18.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 19.82 Bn |
| 10 | Outlook Therapeutics | 93.68 Mn | 82.44 Mn | -8,265.00 | 26.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.89 Mn |
| Dec 31, 2025 | 18.24 Mn |
| Sep 30, 2025 | 18.58 Mn |
| Jun 30, 2025 | 22.39 Mn |
| Mar 31, 2025 | 19.08 Mn |
| Dec 31, 2024 | 17.01 Mn |
| Sep 30, 2024 | 28.82 Mn |
| Jun 30, 2024 | 47.09 Mn |
| Mar 31, 2024 | 59.03 Mn |
| Dec 31, 2023 | 21.68 Mn |
| Sep 30, 2023 | 32.30 Mn |
| Jun 30, 2023 | 44.45 Mn |
| Mar 31, 2023 | 54.02 Mn |
| Dec 31, 2022 | 62.69 Mn |
| Sep 30, 2022 | 28.53 Mn |
| Jun 30, 2022 | 38.59 Mn |
| Mar 31, 2022 | 67.69 Mn |
| Dec 31, 2021 | 78.68 Mn |
| Sep 30, 2021 | 22.81 Mn |
| Jun 30, 2021 | 32.88 Mn |